Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62007TJ0493

    Judgment of the Court of First Instance (Seventh Chamber) of 23 September 2009.
    GlaxoSmithkline SpA and Others v Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM).
    Community trade mark - Invalidity proceedings - Community word mark FAMOXIN - Earlier national word marks LANOXIN - Relative ground for refusal - No likelihood of confusion - Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009) - Proof of use - Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009).
    Cases T-493/07, T-26/08 and T-27/08.

    European Court Reports 2009 II-00175*

    ECLI identifier: ECLI:EU:T:2009:355





    Judgment of the Court of First Instance (Seventh Chamber) of 23 September 2009 – GlaxoSmithkline and Others v OHIM – Serono Genetics Institute (FAMOXIN)

    (Cases T-493/07, T-26/08 and T-27/08)

    Community trade mark – Invalidity proceedings – Community word mark FAMOXIN – Earlier national word marks LANOXIN – Relative ground for refusal – No likelihood of confusion – Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009) – Proof of use – Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009

    Community trade mark – Surrender, revocation and invalidity – Relative grounds of invalidity – Registration contrary to Article 8(1)(b) of Regulation No 40/94 (Council Regulation No 40/94, Art. 52(1)(a)) (see paras 50-57, 73-76)

    Re:

    Three actions brought against the decisions of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 September 2007 (Case R 8/2007-1), 20 November 2007 (Case R 10/2007-1) and 19 November 2007 (Case R 9/2007-1), relating to cancellation proceedings between, on the one hand, GlaxoSmithkline SpA, Laboratórios Wellcome De Portugal L da and The Wellcome Foundation Ltd, and, on the other, Serono Genetics Institute SA.

    Information relating to the case

    Registered Community trade mark subject of the application for a declaration of invalidity:

    Community word mark FAMOXIN for goods and services in Class 5 – Application No 2491298

    Proprietor of the Community trade mark:

    Serono Genetics Institute SA

    Party requesting the declaration of invalidity of the Community trade mark:

    GlaxoSmithkline SpA ; Laboratórios Wellcome de Portugal, Lda ; and The Wellcome Foundation Ltd

    Trade mark right of the party requesting the declaration of invalidity:

    National word mark LANOXIN for goods in Class 5

    Decision of the Cancellation Division:

    Applications dismissed

    Decision of the Board of Appeal:

    Appeals dismissed

    Operative part

    The Court:

    1.

    Joins Cases T-493/07, T-26/08 and T-27/08 for the purposes of the present judgment;

    2.

    Dismisses the actions;

    3.

    Orders GlaxoSmithKline SpA, Laboratórios Wellcome de Portugal, Lda and The Wellcome Foundation Ltd to pay the costs.

    Top